I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received notification from Nasdaq on June 11, 2025, confirming that its American Depositary Shares (ADSs) had maintained a minimum closing bid price of $1.00 for at least 10 consecutive business days, meeting the requirement under Nasdaq Listing Rule 5550(a)(2). This compliance was achieved on June 10, 2025, and Nasdaq has confirmed that the matter is closed. I-Mab's ADSs will continue to be listed and traded on the Nasdaq stock exchange.

Positive

• Company successfully regained Nasdaq listing compliance, avoiding potential delisting
• ADSs maintained required $1.00 minimum bid price for 10 consecutive business days
• Continued listing on Nasdaq ensures broader market access and visibility

Negative

• Previous trading below $1.00 indicates recent market weakness
• Company faced risk of delisting before regaining compliance

ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on June 11, 2025 it received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). The Company’s American Depositary Shares (“ADSs”) will continue to be listed and traded on Nasdaq.

To regain compliance with the Listing Rule, the Company’s ADSs were required to maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days, which was achieved on June 10, 2025. Nasdaq has stated that this matter is now closed.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain a strong tumor-binding property and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.

For more information, please visit www.i-mabbiopharma.com and follow us on LinkedIn and X.

I-Mab Investor & Media Contacts

PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com

FAQ

What did I-Mab (IMAB) do to regain Nasdaq compliance in June 2025?

I-Mab regained compliance by maintaining its ADS price above $1.00 for at least 10 consecutive business days, meeting Nasdaq's minimum bid price requirement under Rule 5550(a)(2).

Will IMAB stock continue trading on Nasdaq after regaining compliance?

Yes, I-Mab's American Depositary Shares will continue to be listed and traded on Nasdaq as the company has regained compliance with listing requirements.

What is I-Mab's main business focus?

I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment.

What was the minimum stock price requirement for IMAB to maintain Nasdaq listing?

IMAB needed to maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days to comply with Nasdaq's listing requirements.

When did IMAB receive confirmation of regaining Nasdaq compliance?

I-Mab received notification from Nasdaq confirming compliance on June 11, 2025, after achieving the requirement on June 10, 2025.